Article Details

Risk Adjusted Net Present Value: What is the current valuation of Roche's Prasinezumab

Retrieved on: 2024-09-08 17:45:12

Tags for this article:

Click the tags to see associated articles and topics

Risk Adjusted Net Present Value: What is the current valuation of Roche's Prasinezumab. View article details on hiswai:

Summary

The article discusses Roche's drug Prasinezumab, focusing on its valuation using GlobalData's risk-adjusted net present value (rNPV) model. This model combines business intelligence tools to integrate risk factors into financial metrics, aligning with tags like Valuation, Fundamental analysis, and Financial economics.

Article found on: www.pharmaceutical-technology.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up